Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 23797379)

1.

Contraindicated initiation of β-blocker therapy in patients hospitalized for heart failure.

Dharmarajan K, Masoudi FA, Spertus JA, Li SX, Krumholz HM.

JAMA Intern Med. 2013 Sep 9;173(16):1547-9. doi: 10.1001/jamainternmed.2013.7717. No abstract available.

2.

Optimizing beta-blocker use after myocardial infarction.

Howard PA, Ellerbeck EF.

Am Fam Physician. 2000 Oct 15;62(8):1853-60, 1865-6. Review.

3.

Caution warranted when defining contraindications in initiating β-blocker therapy.

Miyares MA.

JAMA Intern Med. 2014 Mar;174(3):481. doi: 10.1001/jamainternmed.2013.13698. No abstract available.

PMID:
24590097
4.

Caution warranted when defining contraindications in initiating β-blocker therapy--reply.

Dharmarajan K, Krumholz HM.

JAMA Intern Med. 2014 Mar;174(3):481-2. doi: 10.1001/jamainternmed.2013.13685. No abstract available.

PMID:
24590098
5.
6.

A vital drug for heart attack patients.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 1998 Feb;10(12):1-2. No abstract available.

PMID:
9916578
8.

Evaluation of the management of heart failure in primary care.

Calvert MJ, Shankar A, McManus RJ, Ryan R, Freemantle N.

Fam Pract. 2009 Apr;26(2):145-53. doi: 10.1093/fampra/cmn105. Epub 2009 Jan 18.

9.
10.

Performance measures: Unintended consequences.

Geach T.

Nat Rev Cardiol. 2013 Sep;10(9):488. doi: 10.1038/nrcardio.2013.103. Epub 2013 Jul 9. No abstract available.

PMID:
23836281
11.

Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial.

Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, Adams KF Jr.

Eur J Heart Fail. 2007 Oct;9(10):1064-9. Epub 2007 Aug 24.

12.

Performance measures: better outcomes, not better grades.

Redberg RF.

JAMA Intern Med. 2013 Sep 9;173(16):1549. doi: 10.1001/jamainternmed.2013.7769. No abstract available.

PMID:
23797702
13.

Update of recent clinical trials in heart failure and myocardial infarction.

Richardson M, Cockburn N, Cleland JG.

Eur J Heart Fail. 1999 Mar;1(1):109-15.

PMID:
10937988
14.

Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial.

Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M; IMPACT-HF Investigators and Coordinators.

J Am Coll Cardiol. 2004 May 5;43(9):1534-41.

PMID:
15120808
15.

Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction.

Sial SH, Malone M, Freeman JL, Battiola R, Nachodsky J, Goodwin JS.

J Gen Intern Med. 1994 Nov;9(11):599-605.

PMID:
7853068
16.

Beta-blocker use in patients with acute myocardial infarction treated by hospitalists.

Dall L, Simmons T, Peterson S, Herndon B.

Manag Care Interface. 2000 May;13(5):61-3, 69.

PMID:
11067397
17.

Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.

Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R, Padley RJ, Huang B, Cohen-Solal A.

Eur J Heart Fail. 2009 Mar;11(3):304-11. doi: 10.1093/eurjhf/hfn045. Epub 2009 Jan 21.

18.

Benefits of inpatient initiation of beta-blockers.

Ventura HO.

Am Heart J. 2004 Dec;148(6):944-50. Review.

PMID:
15632876
19.

Defining quality at Catholic Healthcare West.

Bo-Linn GW.

Am J Cardiol. 2000 Mar 9;85(5A):2B-4B.

PMID:
11076124
20.

Current utilization trends for beta-blockers in cardiovascular disease.

Kennedy HL.

Am J Med. 2001 Apr 2;110 Suppl 5A:2S-6S. Review.

PMID:
11259750
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk